classic Hodgkin lymphoma
classic Hodgkin lymphoma
Explore linked clinical trials. Standard reference: MONDO:000934838 results ยท Page 1 of 2
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Allogeneic CD30.CAR-EBVSTs in Patients With Relapsed or Refractory CD30-Positive Lymphomas | Hemic and Lymphatic Diseases, Hodgkins lymphoma, Lymphoma, Extranodal NK-T-Cell, Neoplasms by Histologic Type, T-cell non-Hodgkin lymphoma, classic Hodgkin lymphoma, immune system disorder, immunoproliferative disorder, lymphatic system disorder, lymphoma, lymphoproliferative syndrome, neoplasm | Active, not recruiting | Phase 1 | 2026-10-02 | NCT04288726 | |
| Immunotherapy (Nivolumab or Brentuximab Vedotin) Plus Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage III-IV Classic Hodgkin Lymphoma | Hemic and Lymphatic Diseases, Hodgkin's lymphoma, lymphocytic-histiocytic predominance, Hodgkins lymphoma, Neoplasms by Histologic Type, classic Hodgkin lymphoma, immune system disorder, immunoproliferative disorder, lymphatic system disorder, lymphoma, lymphoproliferative syndrome, neoplasm | Active, not recruiting | Phase 3 | 2026-10-01 | NCT03907488 | |
| Brentuximab Vedotin and Combination Chemotherapy in Treating Children and Young Adults With Stage IIB, Stage IIIB, IVA, or IVB Hodgkin Lymphoma | classic Hodgkin lymphoma | Active, not recruiting | Phase 3 | 2026-10-01 | NCT02166463 | |
| MT2022-60: Ph 2 Study of Pembro+ BEAM With ASCT for Relapsed Hodgkin Lymphoma | classic Hodgkin lymphoma | Recruiting | Phase 2 | 2026-09-29 | NCT06377540 | |
| Ibrutinib and Nivolumab in Treating Patients With Relapsed or Refractory Classical Hodgkin Lymphoma | classic Hodgkin lymphoma | Active, not recruiting | Phase 2 | 2026-09-24 | NCT02940301 | |
| Doxorubicin, Vinblastine, Dacarbazine, Brentuximab Vedotin, and Nivolumab in Treating Patients With Stage I-II Hodgkin Lymphoma | classic Hodgkin lymphoma | Active, not recruiting | Phase 2 | 2026-09-15 | NCT03233347 | |
| Lifestyles Implemented-Survivorship Care Plan In Lymphoma Survivors | B-cell neoplasm, Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, classic Hodgkin lymphoma, diffuse large B-cell lymphoma, immune system disorder, immunoproliferative disorder, lymphatic system disorder, lymphoma, lymphoproliferative syndrome, neoplasm | Recruiting | Not applicable | 2026-09-11 | NCT05934084 | |
| Personalized Reduction of Chemotherapy Intensity Through ctDNA Evaluation for the Treatment of Patients With Advanced Hodgkin Lymphoma | classic Hodgkin lymphoma | Recruiting | Phase 2 | 2026-09-09 | NCT06745076 | |
| A Study About How Blood Cell Growth Patterns Relate to Heart Health After Treatment for Hodgkin Lymphoma | cardiovascular disorder, classic Hodgkin lymphoma, clonal hematopoiesis | Recruiting | Not stated | 2026-08-25 | NCT05705531 | |
| Pembrolizumab in Combination With Chemotherapy for the Treatment of Frail Hodgkin Lymphoma Patients Ineligible for Standard Treatment | classic Hodgkin lymphoma | Recruiting | Phase 2 | 2026-08-20 | NCT07275216 | |
| ctDNA-Guided Therapy for Relapsed/Refractory Hodgkin Lymphoma | Hemic and Lymphatic Diseases, Hodgkin Lymphoma, Adult, Hodgkins lymphoma, Neoplasms by Histologic Type, classic Hodgkin lymphoma, immune system disorder, immunoproliferative disorder, lymphatic system disorder, lymphoma, lymphoproliferative syndrome, neoplasm | Recruiting | Phase 2 | 2026-08-20 | NCT07021989 | |
| A Study of MGD024 in Patients With Relapsed or Refractory Hematologic Malignancies | CD4+/CD56+ hematodermic neoplasm, Chronic Disease, Disease Attributes, Hemic and Lymphatic Diseases, Leukemia, B-Cell, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Mast Cell Activation Disorders, Mastocytosis, Systemic, Myeloproliferative Disorders, Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Connective and Soft Tissue, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Skin and Connective Tissue Diseases, acute myeloid leukemia, aggressive systemic mastocytosis, bone marrow disorder, classic Hodgkin lymphoma, connective tissue neoplasm, hairy cell leukemia, hematologic disorder, hematopoietic and lymphoid system neoplasm, immune system disorder, immunoproliferative disorder, leukemia, lymphatic system disorder, lymphoid leukemia, lymphoma, lymphoproliferative syndrome, malignant histiocytosis, mastocytosis, myelodysplastic syndrome, myeloid leukemia, neoplasm, skin disorder, skin neoplasm | Active, not recruiting | Phase 1 | 2026-07-28 | NCT05362773 | |
| Pembrolizumab Followed by Chemotherapy for the Treatment of Patients With Classical Hodgkin Lymphoma | classic Hodgkin lymphoma | Active, not recruiting | Phase 2 | 2026-07-13 | NCT06164275 | |
| A Study of Pembrolizumab (MK-3475) in Pediatric Participants With an Advanced Solid Tumor or Lymphoma (MK-3475-051/KEYNOTE-051) | Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Germ Cell and Embryonal, Neoplasms, Nerve Tissue, Skin and Connective Tissue Diseases, classic Hodgkin lymphoma, immune system disorder, immunoproliferative disorder, lymphatic system disorder, lymphoma, lymphoproliferative syndrome, melanocytic neoplasm, melanoma, neoplasm, neuroendocrine neoplasm, primitive neuroectodermal tumor, skin disorder, skin neoplasm | Recruiting | Phase 1 / Phase 2 | 2026-07-06 | NCT02332668 | |
| Study of Pembrolizumab With Bendamustine in Hodgkin Lymphoma | Disease Attributes, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Recurrence, classic Hodgkin lymphoma, neoplasm, refractory malignant neoplasm | Recruiting | Phase 2 | 2026-06-23 | NCT04510636 | |
| Itacitinib + Everolimus in Hodgkin Lymphoma | classic Hodgkin lymphoma | Active, not recruiting | Phase 1 / Phase 2 | 2026-06-23 | NCT03697408 | |
| Neurocognitive Assessment in Long-Term Survivors of Lymphoma | B-cell neoplasm, Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, classic Hodgkin lymphoma, diffuse large B-cell lymphoma, immune system disorder, immunoproliferative disorder, lymphatic system disorder, lymphoma, lymphoproliferative syndrome, neoplasm | Not yet recruiting | Not stated | 2026-06-22 | NCT07652476 | |
| Changing Paragidms In The Prognostic Assessment Of Hodgkin Lymphoma | classic Hodgkin lymphoma | Recruiting | Not stated | 2026-05-29 | NCT06822855 | |
| CD30 CAR-T Cells for Low Risk Relapsed Classical Hodgkin Lymphoma | classic Hodgkin lymphoma | Not yet recruiting | Phase 1 | 2026-05-20 | NCT07575893 | |
| Fitness-adapted, Pembrolizumab-based Therapy for Untreated Classical Hodgkin Lymphoma Patients 60 Years of Age and Above | classic Hodgkin lymphoma | Active, not recruiting | Phase 2 | 2026-05-14 | NCT05404945 | |
| Pilot Study of Bone Mineral Density Changes During Anti-PD-1 Immunotherapy | Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Head and Neck Neoplasms, Male Urogenital Diseases, Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Germ Cell and Embryonal, Neoplasms, Nerve Tissue, Skin and Connective Tissue Diseases, Thoracic Neoplasms, Urogenital Diseases, Urogenital Neoplasms, adenocarcinoma, benign urinary system neoplasm, breast disorder, breast neoplasm, bronchial neoplasm, bronchogenic carcinoma, carcinoma, classic Hodgkin lymphoma, epithelial neoplasm, head and neck squamous cell carcinoma, invasive breast carcinoma, kidney cancer, kidney disorder, lung disorder, lung neoplasm, melanocytic neoplasm, melanoma, neoplasm, neuroendocrine neoplasm, non-small cell lung carcinoma, primitive neuroectodermal tumor, renal cell carcinoma, respiratory system disorder, respiratory tract neoplasm, skin disorder, skin neoplasm, squamous cell carcinoma, triple-negative breast carcinoma, urinary system disorder | Recruiting | Not applicable | 2026-05-06 | NCT07555210 | |
| Pianzumab Combined With AVD Regimen in the Treatment of Newly-diagnosed Advanced Classic Hodgkin Lymphoma | classic Hodgkin lymphoma | Recruiting | Phase 2 | 2026-05-01 | NCT05949931 | |
| Nivolumab & Brentuximab Vedotin Consolidation After Autologous SCT in Patients With High-Risk Classical Hodgkin Lymphoma | Hemic and Lymphatic Diseases, Hodgkins lymphoma, Neoplasms by Histologic Type, classic Hodgkin lymphoma, immune system disorder, immunoproliferative disorder, lymphatic system disorder, lymphoma, lymphoproliferative syndrome, neoplasm | Active, not recruiting | Phase 2 | 2026-05-01 | NCT03057795 | |
| CD30 CAR T-cells Post AutoHSCT for Poor-risk Hodgkin Lymphoma | classic Hodgkin lymphoma | Not yet recruiting | Phase 1 / Phase 2 | 2026-04-15 | NCT06617286 | |
| Brentuximab Vedotin for Newly Diagnosed cHL in Chinese CAYA Based on PET/CT Assessment | classic Hodgkin lymphoma | Recruiting | Phase 2 / Phase 3 | 2026-03-19 | NCT06563245 |